Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
  • giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection
  • Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High-Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of October 27, 2020

  • Discovery Projects
  • Phase 1
    29
  • Phase 2
    36
  • Phase 3
    21
  • Registration
    6
  • Total92
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)+ Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 2 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Merkel Cell Carcinoma (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) (E.U.) Registration Product Enhancement Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
recifercept
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Soluable recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy
Achondroplasia (Biologic) Phase 1 New Molecular Entity Biologic
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Go to clinical trial
Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Biologic
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1
Alopecia Areata Phase 2 Product Enhancement Small Molecule
ritlecitinib (PF-06651600)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ankylosing Spondylitis Phase 3 Product Enhancement Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ankylosing Spondylitis (U.S.)
Project advanced
Registration Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
PF-07038124
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical PDE4 Inhibitor
Atopic Dermatitis Phase 1 New Molecular Entity Small Molecule
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK1 Inhibitor
Go to clinical trial
Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.)
Project advanced
Registration New Molecular Entity Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
BRAF-mutant Metastatic Melanoma Brain Metastasis (ORPHAN - U.S.) Phase 2 Product Enhancement Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule